367 results on '"Huhn, Andrew S."'
Search Results
52. Challenges for Women Entering Treatment for Opioid Use Disorder
53. The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use
54. Pain catastrophizing moderates the relationship between chronic pain and insomnia severity in persons with opioid use disorder
55. Promoting Sleep Health to Mitigate the Risk of Non-medical Opioid Use and Opioid-related Adverse Events
56. Predictors of Suicidal Ideation During Residential Substance Use Treatment
57. Fentanyl Absorption, Distribution, Metabolism, and Excretion: Narrative Review and Clinical Significance Related to Illicitly Manufactured Fentanyl
58. Why aren't physicians prescribing more buprenorphine?
59. Daily sleep quality affects drug craving, partially through indirect associations with positive affect, in patients in treatment for nonmedical use of prescription drugs
60. Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype–genotype assessment.
61. Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals
62. Operational definition of precipitated opioid withdrawal
63. A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal.
64. Can initial experiences with drugs predict future drug abuse risks?
65. Recovery Goals and Long-term Treatment Preference in Persons Who Engage in Nonmedical Opioid Use
66. Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder
67. Sleep disturbance as a therapeutic target to improve opioid use disorder treatment.
68. Wireless electroencephalography (EEG) to monitor sleep among patients being withdrawn from opioids: Evidence of feasibility and utility.
69. Pharmacological interventions for insomnia disorder in adults
70. Patient perceptions of higher-dose naloxone nasal spray for opioid overdose
71. Opioid Use Disorder Treatment in the Fentanyl Era
72. Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper
73. Positive associations between cannabis and alcohol use polygenic risk scores and phenotypic opioid misuse among African-Americans
74. Commentary on Zolopa et al.: Trauma as an impediment to successful aging and a precipitant of opioid and stimulant use among older adults
75. Evaluation of Stigma Related to Perceived Risk for Coronavirus-19 Transmission Relative to the Other Stigmatized Conditions Opioid Use and Depression
76. Worsening sleep quality across the lifespan and persistent sleep disturbances in persons with opioid use disorder
77. Latent trajectories of anxiety and depressive symptoms among adults in early treatment for nonmedical opioid use
78. Promoting sleep health to mitigate the risk of nonmedical opioid use and opioid-related adverse events.
79. Adults With Opioid and Methamphetamine Co-use Have Lower Odds of Completing Short-Term Residential Treatment Than Other Opioid Co-use Groups: A Retrospective Health Services Study
80. Evidence of Buprenorphine-precipitated Withdrawal in Persons Who Use Fentanyl
81. Attitudes Toward Organ Donation for Persons Who Have a Substance Use Disorder Relative to Other Health Conditions
82. Early Childhood Behavioral and Academic Antecedents of Lifetime Opioid Misuse among Urban Youth.
83. Integration of Patient-reported Outcomes Assessment Into Routine Care for Patients Receiving Residential Treatment for Alcohol and/or Substance Use Disorder
84. Comprehensive pain management as a frontline treatment to address the opioid crisis
85. Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone
86. Clinical correlates of drug‐related dreams in opioid use disorder
87. Shared Genetic Etiology between Cortical Brain Morphology and Tobacco, Alcohol, and Cannabis Use
88. Substance Use in the Performing Artist with Chronic Pain
89. Promoting harm reduction as a treatment outcome in substance use disorders.
90. The discounting of death: Probability discounting of heroin use by fatal overdose likelihood and drug purity.
91. Protracted renal clearance of fentanyl in persons with opioid use disorder
92. The impact of naturalistic cannabis use on self-reported opioid withdrawal
93. Shared genetic etiology between cortical brain morphology and tobacco, alcohol, and cannabis use
94. Early Childhood Behavioral and Academic Antecedents of Lifetime Opioid Misuse among Urban Youth
95. Treatment Disruption and Childcare Responsibility as Risk Factors for Drug and Alcohol Use in Persons in Treatment for Substance Use Disorders During the COVID-19 Crisis
96. Differential adoption of opioid agonist treatments in detoxification and outpatient settings
97. Trends in first-time treatment admissions for older adults with alcohol use disorder: Availability of medical and specialty clinical services in hospital, residential, and outpatient facilities
98. Shared Genetic Etiology between Cortical Brain Morphology and Tobacco, Alcohol, and Cannabis Use.
99. Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone
100. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.